INDIVIOR Business Summary

Indivior PLC (NASDAQ: INDV), recently redomiciled as Indivior Pharmaceuticals, Inc. in January 2026, is a specialty pharmaceutical leader focused on the treatment of substance use disorders (SUD) and serious mental illnesses. The company operates a product-centric revenue model, generating the vast majority of its income through the sale of proprietary addiction therapies, most notably SUBLOCADE (extended-release buprenorphine) and SUBOXONE Film. As of early 2026, the business is structured around its "Action Agenda," specifically Phase II ("Accelerate"), which prioritizes the expansion of SUBLOCADE dispense units in the U.S. market to drive a projected 2026 revenue range of $1.13 billion to $1.20 billion. Indivior maintains a dominant position in the opioid use disorder (OUD) market, competing directly against Camurus (Brixadi), Alkermes (Vivitrol), and generic manufacturers such as Dr. Reddy’s and Alvogen. It distinguishes itself through its long-acting injectable technology and a specialized commercial infrastructure tailored to the complex U.S. organized provider and justice system channels. Originally spun off from Reckitt Benckiser in 2014, the company is currently led by Chief Executive Officer Joseph "Joe" Ciaffoni, who assumed the role in May 2025 after serving as CEO of Collegium Pharmaceutical and holding senior leadership positions at Biogen and Endo International. He is supported by Chief Financial Officer Ryan Preblick, a veteran executive who has been with Indivior since 2012 and was appointed CFO in 2020, and Chief Commercial Officer Patrick Barry, who joined in 2025 with extensive experience from Collegium and Mallinckrodt. The board is chaired by Dr. David Wheadon, a former AstraZeneca and Abbott Laboratories executive with deep regulatory expertise. A notable institutional influence is Oaktree Capital Management, which maintains a significant ownership stake and a relationship agreement that includes board representation, reflecting the company's ongoing focus on capital allocation and operational efficiency following its transition to a primary U.S. listing.